跳至主要内容
临床试验/NCT03731910
NCT03731910Unknown不适用

Short Term Magnetic Resonance Imaging (MRI) for Treatment Response Evaluation and Prognosis Prediction in Patients With Hepatocellular Carcinoma (HCC) Treated With Transarterial Radioembolization (TARE)

Seoul National University Hospital1 个研究点 分布在 1 个国家目标入组 35 人开始时间: 2018年12月11日最近更新:
适应症

试验速览

阶段
不适用
入组人数
35
试验地点
1
主要终点
Treatment response mRECIST

研究概览

简要总结

This study aims to investigate the value of early change at MRI in HCC treated with TARE, for evaluation/prediction of treatment response and prognosis.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Intermediate or locally advanced HCC according to Hong Kong Liver Cancer guideline
  • Scheduled for transarterial radioembolization (TARE)
  • sign informed consent

排除标准

  • Any absolute or relative contra-indication of contrast-enhanced MRI
  • History of other local treatment before TARE in 3 weeks

结局指标

主要结局

Treatment response mRECIST

时间窗: 1 month after last MRI

treatment response using mRECIST

次要结局

  • Tumor diffusion(1 months after last MRI)
  • Tumor perfusion(1 months after last MRI)
  • Treatment response LI-RADS(1 months after last MRI)
  • Treatment response volumetric(1 months after last MRI)
  • Time to Progression(24 months after TARE)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeong Min Lee

Professor

Seoul National University Hospital

研究点 (1)

Loading locations...

相似试验